Cargando…
Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020
The overall aging of the world population has contributed to the continuous upward trend in the incidence of prostate cancer (PC). Trials on PC therapy have been extensively performed, but no study has analyzed the overall trends and characteristics of these trials, especially for those carried out...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167212/ https://www.ncbi.nlm.nih.gov/pubmed/34084744 http://dx.doi.org/10.3389/fonc.2021.647110 |
_version_ | 1783701647199830016 |
---|---|
author | Chen, Kun Jiang, Kehua Tang, Lannan Chen, Xiaolong Hu, Jianxin Sun, Fa |
author_facet | Chen, Kun Jiang, Kehua Tang, Lannan Chen, Xiaolong Hu, Jianxin Sun, Fa |
author_sort | Chen, Kun |
collection | PubMed |
description | The overall aging of the world population has contributed to the continuous upward trend in the incidence of prostate cancer (PC). Trials on PC therapy have been extensively performed, but no study has analyzed the overall trends and characteristics of these trials, especially for those carried out in China. This study aimed to provide insights on the future direction of drug development in PC, thus supplying essential supportive data for stakeholders, including researchers, patients, investors, clinicians, and pharmaceutical industry. The details of the clinical trials of drug therapies for PC during January 1, 2010, to January 1, 2020, were collected from Pharmaprojects. A total of 463 clinical trials on different therapies with 132 different drugs were completed. The long-acting endocrine therapy with few side effects, radiotherapy combined with immune checkpoint inhibitors, gene-targeted chemotherapeutics, and novel immunotherapeutic products changed the concept of PC treatment. In mainland China, 31 trials with 19 drugs have been completed in the 10 assessment years. China has initiated a few trials investigating a limited number of drug targets, centered in a markedly uneven geographical distribution of leading clinical trial units; hence, the development of PC drugs has a long way to go. Given the large patient pool, China deserves widespread attention for PC drug research and development. These findings might have a significant impact on scientific research and industrial investment. |
format | Online Article Text |
id | pubmed-8167212 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81672122021-06-02 Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020 Chen, Kun Jiang, Kehua Tang, Lannan Chen, Xiaolong Hu, Jianxin Sun, Fa Front Oncol Oncology The overall aging of the world population has contributed to the continuous upward trend in the incidence of prostate cancer (PC). Trials on PC therapy have been extensively performed, but no study has analyzed the overall trends and characteristics of these trials, especially for those carried out in China. This study aimed to provide insights on the future direction of drug development in PC, thus supplying essential supportive data for stakeholders, including researchers, patients, investors, clinicians, and pharmaceutical industry. The details of the clinical trials of drug therapies for PC during January 1, 2010, to January 1, 2020, were collected from Pharmaprojects. A total of 463 clinical trials on different therapies with 132 different drugs were completed. The long-acting endocrine therapy with few side effects, radiotherapy combined with immune checkpoint inhibitors, gene-targeted chemotherapeutics, and novel immunotherapeutic products changed the concept of PC treatment. In mainland China, 31 trials with 19 drugs have been completed in the 10 assessment years. China has initiated a few trials investigating a limited number of drug targets, centered in a markedly uneven geographical distribution of leading clinical trial units; hence, the development of PC drugs has a long way to go. Given the large patient pool, China deserves widespread attention for PC drug research and development. These findings might have a significant impact on scientific research and industrial investment. Frontiers Media S.A. 2021-05-12 /pmc/articles/PMC8167212/ /pubmed/34084744 http://dx.doi.org/10.3389/fonc.2021.647110 Text en Copyright © 2021 Chen, Jiang, Tang, Chen, Hu and Sun https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Chen, Kun Jiang, Kehua Tang, Lannan Chen, Xiaolong Hu, Jianxin Sun, Fa Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020 |
title | Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020 |
title_full | Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020 |
title_fullStr | Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020 |
title_full_unstemmed | Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020 |
title_short | Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020 |
title_sort | analysis of clinical trials on therapies for prostate cancer in mainland china and globally from 2010 to 2020 |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167212/ https://www.ncbi.nlm.nih.gov/pubmed/34084744 http://dx.doi.org/10.3389/fonc.2021.647110 |
work_keys_str_mv | AT chenkun analysisofclinicaltrialsontherapiesforprostatecancerinmainlandchinaandgloballyfrom2010to2020 AT jiangkehua analysisofclinicaltrialsontherapiesforprostatecancerinmainlandchinaandgloballyfrom2010to2020 AT tanglannan analysisofclinicaltrialsontherapiesforprostatecancerinmainlandchinaandgloballyfrom2010to2020 AT chenxiaolong analysisofclinicaltrialsontherapiesforprostatecancerinmainlandchinaandgloballyfrom2010to2020 AT hujianxin analysisofclinicaltrialsontherapiesforprostatecancerinmainlandchinaandgloballyfrom2010to2020 AT sunfa analysisofclinicaltrialsontherapiesforprostatecancerinmainlandchinaandgloballyfrom2010to2020 |